MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
21.19
+0.18
+0.86%
Closed 19:59 02/09 EST
OPEN
20.92
PREV CLOSE
21.01
HIGH
21.35
LOW
20.75
VOLUME
1.09M
TURNOVER
0
52 WEEK HIGH
22.73
52 WEEK LOW
8.58
MARKET CAP
1.84B
P/E (TTM)
-5.8771
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SNDX last week (0202-0206)?
Weekly Report · 1d ago
Top Syndax Executives Quietly Unload Shares in Notable Insider Move
TipRanks · 3d ago
Syndax Pharmaceuticals nimmt am Guggenheim Emerging Outlook: Biotech Summit teil
Reuters · 4d ago
Syndax Pharmaceuticals Grants Stock Options to New Employees Under Inducement Plan
Reuters · 5d ago
SYNDAX PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
Assessing Syndax Pharmaceuticals (SNDX) Valuation After Recent Share Price Momentum And Mixed Performance
Simply Wall St · 5d ago
Syndax Pharmaceuticals (SNDX) Receives a Buy from Barclays
TipRanks · 6d ago
Syndax price target raised to $28 from $27 at BofA
TipRanks · 6d ago
More
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.